🇺🇸 HIDAC (high dose cytarabine) in United States

8 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 8

Most-reported reactions

1. Febrile Neutropenia — 2 reports (25%)
2. Acute Hepatic Failure — 1 report (12.5%)
3. Anaemia — 1 report (12.5%)
4. Atelectasis — 1 report (12.5%)
5. Bone Marrow Failure — 1 report (12.5%)
6. Pneumonia — 1 report (12.5%)
7. Thrombocytopenia — 1 report (12.5%)

Source database →

Frequently asked questions

Is HIDAC (high dose cytarabine) approved in United States?

HIDAC (high dose cytarabine) does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for HIDAC (high dose cytarabine) in United States?

Pfizer is the originator. The local marketing authorisation holder may differ — check the official source linked above.